Michelle C Janelsins1, Charles E Heckler2, Bryan D Thompson2, Robert A Gross3, Lisa A Opanashuk4, Deborah A Cory-Slechta4. 1. Department of Surgery-Cancer Control, University of Rochester, Rochester, NY, United States. Electronic address: michelle_janelsins@urmc.rochester.edu. 2. Department of Surgery-Cancer Control, University of Rochester, Rochester, NY, United States. 3. Department of Neurology, University of Rochester, Rochester, NY, United States. 4. Department of Environmental Medicine, University of Rochester, Rochester, NY, United States.
Abstract
BACKGROUND: Cyclophosphamide chemotherapy is a mainstay of adjuvant breast cancer treatment. Unfortunately, this drug is associated with cognitive impairments in cancer patients that may accelerate cognitive aging. Memory is particularly affected in many patients. In order to better understand the precise cognitive impairments caused by this chemotherapy agent, we investigated a clinically relevant dose and administration paradigm on delayed spatial memory abilities in C57BL/6 mice. We utilized a delayed alternation paradigm similar to a delayed match to sample paradigm reported to be sensitive in human neurotoxicology research. METHODS: A dose of 200mg/kg cyclophosphamide was administered intravenously (at weekly intervals) for 4 weeks to C57BL/6 mice starting at 6 ½ months of age. Memory was tested in mice using a reward-based delayed spatial alternation paradigm with delay values of 1.5, 3, 6.1, 12.4 and 25s presented randomly over 80 sessions (16 reinforcers per session), and testing began at the initiation of chemotherapy through 3 months. RESULTS: At the longest delay, i.e., that requiring the greatest memory, mice treated with chemotherapy exhibited a significant decline over time in percent correct which leveled off compared to controls that continued to improve slightly. CONCLUSIONS: Our clinically relevant model shows cyclophosphamide chemotherapy causes a slight decline in delayed spatial memories at the longest delay that is sustained over time as mice age.
BACKGROUND:Cyclophosphamide chemotherapy is a mainstay of adjuvant breast cancer treatment. Unfortunately, this drug is associated with cognitive impairments in cancerpatients that may accelerate cognitive aging. Memory is particularly affected in many patients. In order to better understand the precise cognitive impairments caused by this chemotherapy agent, we investigated a clinically relevant dose and administration paradigm on delayed spatial memory abilities in C57BL/6 mice. We utilized a delayed alternation paradigm similar to a delayed match to sample paradigm reported to be sensitive in human neurotoxicology research. METHODS: A dose of 200mg/kg cyclophosphamide was administered intravenously (at weekly intervals) for 4 weeks to C57BL/6 mice starting at 6 ½ months of age. Memory was tested in mice using a reward-based delayed spatial alternation paradigm with delay values of 1.5, 3, 6.1, 12.4 and 25s presented randomly over 80 sessions (16 reinforcers per session), and testing began at the initiation of chemotherapy through 3 months. RESULTS: At the longest delay, i.e., that requiring the greatest memory, mice treated with chemotherapy exhibited a significant decline over time in percent correct which leveled off compared to controls that continued to improve slightly. CONCLUSIONS: Our clinically relevant model shows cyclophosphamide chemotherapy causes a slight decline in delayed spatial memories at the longest delay that is sustained over time as mice age.
Authors: Brent J Small; Kerri Sharp Rawson; Erin Walsh; Heather S L Jim; Tiffany F Hughes; Lindsay Iser; Michael A Andrykowski; Paul B Jacobsen Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Michiel B de Ruiter; Liesbeth Reneman; Willem Boogerd; Dick J Veltman; Frits S A M van Dam; Aart J Nederveen; Epie Boven; Sanne B Schagen Journal: Hum Brain Mapp Date: 2010-07-28 Impact factor: 5.038
Authors: Tim A Ahles; Andrew J Saykin; Walter W Noll; Charlotte T Furstenberg; Stephen Guerin; Bernard Cole; Leila A Mott Journal: Psychooncology Date: 2003-09 Impact factor: 3.894
Authors: Deblina Dey; Vipan K Parihar; Gergely G Szabo; Peter M Klein; Jenny Tran; Jonathan Moayyad; Faizy Ahmed; Quynh-Anh Nguyen; Alexandria Murry; David Merriott; Brandon Nguyen; Jodi Goldman; Maria C Angulo; Daniele Piomelli; Ivan Soltesz; Janet E Baulch; Charles L Limoli Journal: Radiat Res Date: 2020-03-05 Impact factor: 2.841
Authors: Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann Journal: Drug Saf Date: 2022-05-23 Impact factor: 5.606
Authors: Michelle C Janelsins; Charles E Heckler; Luke J Peppone; Tim A Ahles; Supriya G Mohile; Karen M Mustian; Oxana Palesh; Ann M O'Mara; Lori M Minasian; Annalynn M Williams; Allison Magnuson; Jodi Geer; Shaker R Dakhil; Judith O Hopkins; Gary R Morrow Journal: J Clin Oncol Date: 2018-09-21 Impact factor: 44.544
Authors: Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2021-11-02 Impact factor: 5.153